Evidence map›Paper›PMID 41366426›Full record

ReviewJournal of nanobiotechnology2025

Macrophage membrane-coated nanoparticles in inflammatory diseases: from bioinspired design to translational potential.

Yuyue Hou, Ruolin Wu, Yan Zhou, Chenru Yin, Yongkang Gai, Dawei Jiang, Keshan Wang, Xiaotian Xia

Abstract readReview
In one paragraph

Review in Journal of nanobiotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Size-Dependent Immunomodulatory Effects of FeMolecules (Basel, Switzerland) · 2026
    Article
  12. Review
  13. Review
  14. Article
  15. mFrontiers in immunology · 2026
    Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yuyue HouDepartment of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, No.1277 Jiefang Avenue, Wuhan, 430022, Hubei, China.
Ruolin WuDepartment of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, No.1277 Jiefang Avenue, Wuhan, 430022, Hubei, China.
Yan ZhouDepartment of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, No.1277 Jiefang Avenue, Wuhan, 430022, Hubei, China.
Chenru YinHubei Academy of Scientific and Technical Information, Wuhan, China.
Yongkang GaiDepartment of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, No.1277 Jiefang Avenue, Wuhan, 430022, Hubei, China.
Dawei JiangDepartment of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, No.1277 Jiefang Avenue, Wuhan, 430022, Hubei, China. daweijiang@hust.edu.cn.
Keshan WangDepartment of Urology, Tongji Medical College, Union Hospital, Huazhong University of Science and Technology, Wuhan, 430022, China. wks4869@hust.edu.cn.
Xiaotian XiaDepartment of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, No.1277 Jiefang Avenue, Wuhan, 430022, Hubei, China. xiaotian_xia@hust.edu.cn.

Funding

Hubei Provincial Natural Science Foundation Project 2024AFB633Interdisciplinary Research Program of HUST 5003530229Natural Science Foundation of Wuhan 2024040801020349
6 · The paper itself

Abstract

Inflammatory diseases, including autoimmune, infectious, and metabolic disorders, remain major global health challenges due to their complex pathogenesis and limited therapeutic options. In recent years, bioinspired nanotechnology has emerged as a transformative approach in precision medicine. Among various strategies, macrophage membrane-coated nanoparticles (MΦ-NPs) have gained significant attention for their excellent biocompatibility, immune evasion, and lesion-targeting capabilities. This review systematically outlines the construction strategies, biological characteristics, and functional mechanisms of MΦ-NPs. It details the fabrication process, including core material design, macrophage membrane extraction and functionalization, and efficient membrane-core assembly. The current applications of MΦ-NPs in the diagnosis and treatment of non-tumor inflammatory diseases, such as bacterial and viral infections, rheumatoid arthritis, inflammatory bowel disease, atherosclerosis, and bone tissue repair are comprehensively reviewed. Special emphasis is placed on their unique behavior in inflammatory microenvironments, where they enable site-specific drug delivery, prolonged circulation, and immune modulation, offering innovative solutions to long-standing therapeutic challenges. Furthermore, we discuss the emerging hybrid membrane systems that integrate macrophage membranes with those of red blood cells, platelets, or tumor cells, enhancing both targeting and therapeutic performance. Despite promising preclinical results, challenges remain regarding large-scale production, clinical translation, and biosafety evaluation. By integrating insights from nanotechnology, immunology, and translational medicine, this review provides a comprehensive perspective on the design, functionality, and therapeutic frontiers of MΦ-NPs. Continued advances in biomimetic nanomedicine are expected to drive the development of next-generation anti-inflammatory therapies with high precision and minimal systemic toxicity.

Indexed as

Cell MembraneInflammationMacrophagesNanoparticlesAnimalsDrug Delivery SystemsHumansTranslational Research, BiomedicalBiomimetic nanomedicineHybrid cell membranesImmune modulationInflammatory diseasesMacrophage membrane-coated nanoparticlesNon-tumor pathologyTargeted drug deliveryTranslational nanotechnology

Identifiers

PMID41366426
PMCPMC12801971

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.